SOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken Sells 2,424 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) President Ross Muken sold 2,424 shares of SOPHiA GENETICS stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $4.87, for a total value of $11,804.88. Following the completion of the sale, the president owned 698,097 shares in the company, valued at approximately $3,399,732.39. This trade represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $5,666.57.

SOPHiA GENETICS Stock Down 0.8%

SOPHiA GENETICS stock opened at $4.86 on Thursday. The stock’s 50 day moving average price is $4.77 and its 200 day moving average price is $4.68. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. The company has a market cap of $332.86 million, a PE ratio of -9.53 and a beta of 1.04. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. On average, sell-side analysts predict that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: CEO Jurgi Camblong executed two Rule 10b5‑1 sales (2,600 and 2,500 shares at ~$4.85–4.86). CEO still holds ~3.7M shares. SEC filing
• Neutral Sentiment: CFO George Cardoza reported multiple small sales (~2,520; 2,413 shares) under a 10b5‑1 plan to cover taxes; remaining holdings stay large (~292–295k shares). SEC filing
• Neutral Sentiment: CTO Abhimanyu Verma sold several tranches (2,519; 1,030 shares) under a 10b5‑1 plan; still owns ~204–205k shares. SEC filing
• Neutral Sentiment: President Ross Muken and other senior managers (Philippe Menu, Zhenyu Xu, Manuela Valente, Well Daan Van, Kevin Puylaert) reported multiple planned sales of ~600–2,700 shares each to cover tax obligations; each filing cites Rule 10b5‑1 plans. Representative filings: Menu, Xu, Valente. Menu SEC filing
• Neutral Sentiment: Collectively the insider sales are modest relative to total insider holdings and were executed under pre‑arranged plans (tax withholding stated as purpose), which reduces negative informational signal but can still create short-term selling pressure.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $55,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $54,000. Archon Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after acquiring an additional 14,342 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of SOPHiA GENETICS by 169.5% in the fourth quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock valued at $388,000 after acquiring an additional 52,200 shares in the last quarter. Finally, Polen Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $102,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SOPH has been the topic of several research reports. BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Guggenheim upped their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.